Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
AFT Pharmaceuticals (AFT NZ)
Watchlist
60
Analysis
Health Care
•
New Zealand
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products. The Company offers medicines for allergy, cough, cold, and flu, eye care, pain management, and laxatives. AFT Pharmaceuticals serves customers worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
AFT Pharmaceuticals
•
03 Dec 2022 08:01
•
Broker
AFT Pharmaceuticals: 1H23 Result — A Few Sniffles
AFT Pharmaceuticals' (AFT) 1H23 result highlighted ongoing strong underlying revenue momentum which was ahead of our expectations, but this was...
Forsyth Barr
Follow
393 Views
Share
bearish
•
AFT Pharmaceuticals
•
01 Dec 2022 08:01
•
Broker
AFT Pharmaceuticals (AFT): 1H23 Result – Initial Impressions
AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m...
Forsyth Barr
Follow
394 Views
Share
bullish
•
AFT Pharmaceuticals
•
18 Oct 2022 08:01
•
Broker
AFT Pharmaceuticals: A Picture of Health; OUTPERFORM
We initiate full coverage of AFT Pharmaceuticals (AFT) with a 12 month target price of NZ$5.00 and an OUTPERFORM rating; we think the market under...
Forsyth Barr
Follow
238 Views
Share
bullish
•
AFT Pharmaceuticals
•
26 Nov 2021 08:10
•
Broker
AFT Pharmaceuticals: 1H22 Result — A Bump in the Road
AFT Pharmaceuticals1H22 Result — A Bump in the Road RESEARCH INSIGHTS AFT Pharmaceuticals (AFT) reported a lower than expected underlying 1H22...
Forsyth Barr
Follow
880 Views
Share
bullish
•
AFT Pharmaceuticals
•
25 Nov 2021 08:36
•
Broker
AFT Pharmaceuticals (AFT): 1H22 Result – Initial Impressions
AFT Pharmaceuticals (AFT)1H22 Result – Initial Impressions AFT Pharmaceuticals (AFT) reported a 1H22 result below expectations, but significantly...
Forsyth Barr
Follow
912 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x